Overview
Corporate Profile
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing novel cell therapies with the potential to cure difficult-to-treat cancers and rare, serious hematologic diseases. We are leveraging our proprietary nicotinamide-based cell expansion technology, or NAM technology, to develop product candidates designed to address the limitations of cell therapies.
Copyright West LLC. Minimum 15 minutes delayed.
Latest News
View All
Mar 21, 2019
Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
Read More
Feb 25, 2019
Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Read More
Feb 23, 2019
Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting
Read More
Feb 21, 2019
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Read More
Feb 19, 2019
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
Read More
Feb 14, 2019
Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
Read More
Jan 24, 2019
Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
Read More
Dec 04, 2018
Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
Read More
Dec 03, 2018
Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting
Read More
Nov 28, 2018
Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Read More
Nov 01, 2018
Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting
Read More
Sep 18, 2018
Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman
Read More
Aug 06, 2018
Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications
Read More
Jul 23, 2018
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Read More
Jul 17, 2018
Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation
Read More
Jun 18, 2018
Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma
Read More
Upcoming Events
More events are coming soon.
Recent Events
Investor & Media Contact
Jaren Irene Madden
Vice President of Investor Relations and Corporate Communications
Gamida Cell Ltd.
IRPR@gamida-cell.com
